Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60
Sionna Therapeutics
Sionna Therapeutics SION | 0.00 |
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:
SION) with a Buy and raises the price target from $50 to $60.
